Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 36

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 36
---
 healthcare fraud and 
 abuse, and U.S. Food and Drug Administration or international regulations related to product approval; and        |

| • |     | the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require 
 additional actions before or after approval, or to take enforcement action.                                  |

Additional information and detailed discussion of these risks, uncertainties and other potential factors that could affect STAAR’s business and performance and cause actual results or outcomes to differ materially from the results, performance or achievements addressed in STAAR’s forward-looking statements is included in STAAR’s other filings with the SEC, including in the section of this proxy statement titled “ Risk Factors” andsections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of STAAR’s most recently filed periodic reports on Form 10-Kand Form 10-Qand subsequent filings. STAAR assumes no obligation to update its forward-looking statements, which speak as of their respective dates, whether as a result of new information, future events or otherwise. -22-

RISK FACTORS In addition to the other information included and incorporated by reference into this proxy statement, including the matters addressed in the section entitled “Special Note Regarding Forward-Looking Statements,” you should be aware of and carefully consider the following risks and uncertainties that are applicable to the Merger Agreement, the Merger and STAAR before deciding whether to vote for the Merger Proposal and the Compensation Proposal. You should also consider the risks relating to STAAR’s business and ownership of STAAR common stock contained in the section titled “Risk Factors” in STAAR’s Annual Report on Form 10-Kfor the fiscal year ended December 27, 2024, STAAR’s Quarterly Report on Form 10-Qfor the quarterly period ended June 27, 2025, and in any documents STAAR subsequently files with the SEC, which are incorporated into this proxy statement by reference. See “Where You Can Find More Information.” The announcement and pendency of STAAR’s proposed acquisition by Alcon could adversely impact STAAR’s business, financial condition, and results of operations. Uncertainty about the effect of the Merger on STAAR’s employees, distributors, customers, and other parties may have an adverse effect on STAAR’s business, financial condition, and results of operations regardless of whether the Merger is completed. These risks to STAAR’s business include the following, all of which could be exacerbated by a delay in the completion of the Merger: